Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2017 Filed Jun 5, 2017 19:41 UTC |
CHANEY PAUL GDirector
|
Exercise / conversionCommon Stock | 17,570 | $0.65 | $11,420.50 |
DisclosureSEC source: 0001144204-17-031102 · v468441_4.xml · nonDerivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 20:20 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-028875 · v467587_4.xml · derivative · entry 1 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option became exercisable immediately upon grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 20:19 UTC |
FROM STEPHENDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-028874 · v467586_4.xml · derivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option became exercisable immediately upon grant. Read SEC document |
| May 15, 2017 Filed May 15, 2017 20:51 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,285 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001144204-17-027562 · v467081_4.xml · derivative · entry 2 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,285 shares Expires 2017-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable immediately at the time of grant. Read SEC document |
| May 15, 2017 Filed May 15, 2017 20:51 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
Exercise / conversionCommon Stock | 7,285 | $0.65 | $4,735.25 |
DisclosureSEC source: 0001144204-17-027562 · v467081_4.xml · nonDerivative · entry 1 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2017 Filed Mar 21, 2017 20:47 UTC |
Ventech Capital II10% owner
|
SaleCommon Stock | 4,419 | $2.80 | $12,384.69 |
DisclosureSEC source: 0001144204-17-015872 · v462368_4.xml · nonDerivative · entry 1 Ventech Capital II · CIK 0001604072 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,431,814 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $2.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 07, 2017 Filed Mar 7, 2017 17:52 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 8,700 | $2.83 | $24,621.00 |
DisclosureSEC source: 0001144204-17-013286 · v461341_4.xml · nonDerivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,842 Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC |
GOLDBERG MORTONDirector
|
SaleCommon Stock | 8,919 | $3.00 | $26,757.00 |
DisclosureSEC source: 0001144204-17-012941 · v461231_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,441 Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 17:25 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 41,700 | $2.60 | $108,420.00 |
DisclosureSEC source: 0001144204-17-012198 · v460907_4.xml · nonDerivative · entry 2 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By husband Disclosed balance after: 41,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.69, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 17:25 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 54,200 | $2.59 | $140,378.00 |
DisclosureSEC source: 0001144204-17-012198 · v460907_4.xml · nonDerivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,142 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.70, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:24 UTC |
GOLDBERG MORTONDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,083 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001144204-17-012195 · v460895_4.xml · derivative · entry 2 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,917 Underlying: Common Stock · 1,083 shares Expires 2026-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2014 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on January 25, 2017, with 2.78% of the shares underlying the option vesting monthly thereafter. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:24 UTC |
GOLDBERG MORTONDirector
|
Exercise / conversionCommon Stock | 1,083 | $1.70 | $1,841.10 |
DisclosureSEC source: 0001144204-17-012195 · v460895_4.xml · nonDerivative · entry 1 GOLDBERG MORTON · CIK 0001619731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:16 UTC |
Wirostko BarbaraChief Medical Officer
|
GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006501 · v458599_4.xml · nonDerivative · entry 1 Wirostko Barbara · CIK 0001669087 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,942 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:16 UTC |
Mann BrendaVP of Research & Development
|
GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006505 · v458601_4.xml · nonDerivative · entry 1 Mann Brenda · CIK 0001668858 · VP of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,751 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 21:16 UTC |
MANZO MICHAEL P.Vice President of Engineering
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001144204-17-006504 · v458600_4.xml · derivative · entry 1 MANZO MICHAEL P. · CIK 0001620189 · Vice President of Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-02-06 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 21:15 UTC |
FROM STEPHENDirector · President and CEO
|
GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006500 · v458598_4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,965 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:27 UTC |
Romano SarahInterim CFO
|
GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006751 · v458795_4.xml · nonDerivative · entry 1 Romano Sarah · CIK 0001697536 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 20:15 UTC |
FROM STEPHENDirector · President and CEO
|
PurchaseCommon Stock | 15,000 | $1.49 | $22,338.00 |
DisclosureSEC source: 0001144204-16-124265 · v448959_4.xml · nonDerivative · entry 1 FROM STEPHEN · CIK 0001620137 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,965 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.479 to $1.509, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.